Oncology Views & Analysis

Views & Analysis

ASCO 2019 and the future of oncology

ASCO 2019 – phase I data generates hope for the future

Sometimes interesting stories from the ASCO conference are the phase I data that generates hope for the future. One such story at ASCO 2019 was the data on Amgen’s KRAS

ASCO 2019 and the future of oncology

ASCO 2019 - Kantar considers MacroGenics' phase 3 SOPHIA tri...

Kantar analyst Katie Stockstill discusses the results of phase 3 SOPHIA trial that were presented on the last day of ASCO 2019. MacroGenics' trial compared its margetuximab candida

ASCO 2019 Live coverage

ASCO 2019 day five

Exclusive live coverage from day five of the American Society of Clinical Oncology's annual meeting in Chicago. • To view all of our coverage from the preeminent cancer event, prod

Videos

ASCO 2019 - Enfortumab comes out fighting in bladder cancer

At ASCO 2019, results were presented from the phase II EV-201 trial, which evaluated antibody drug conjugate (ADC) enfortumab vedotin in relapsed patients with locally advanced or metastati

Videos

Kantar video image ASCO 2019 clinical practices

ASCO 2019 - Kantar highlights a selection of exciting Phase ...

At ASCO, a lot of attention is given to the results of the large, clinical practices changing phase III studies, but the future is also here. Early phase I and II trials that test

ASCO 2019 and the future of oncology

ASCO 2019 - Kantar debates results from the KEYNOTE-062 tria...

There were a number of debate-worthy outcomes from the KEYNOTE-062 trial that was presented at ASCO 2019 in Chicago yesterday. The study looked at Merck & Co's Keytruda as a fi

ASCO 2019 – phase I data generates hope for the future

ASCO 2019 - Kantar considers MacroGenics' phase 3 SOPHIA tri...

ASCO 2019 day five

ASCO 2019 - Enfortumab comes out fighting in bladder cancer

ASCO 2019 - Kantar highlights a selection of exciting Phase ...

ASCO 2019 - Kantar debates results from the KEYNOTE-062 tria...

AI specialist Chai Discovery raises $400m

Discover a new era of healthcare panel engagement: Grounded ...

Views & Analysis

Editor's Picks